Psoriatic arthritis

Questions discussed in this category

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

3 Answers available

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

3 Answers available

How do you manage psoriatic arthritis in patients who are planning to start treatment with checkpoint inhibitors for underlying malignancy?

2 Answers available

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

1 Answer available

Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?

1 Answer available

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

1 Answer available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

Would you use an IL-17 inhibitor for a psoriatic arthritis patient with inactive inflammatory bowel disease?

1 Answer available

Would you use an anti-IL 17 over an anti-TNFa as your first line biologic in psoriatic arthritis?

Have the SPIRIT H2H and EXCEED data changed your practice?

1 Answer available

What is the preferred DMARD in active spondyloarthropathy with psoriasis and sacroiliitis features in the setting of treated hepatitis C with negative viral load?

In patients refractory to NSAIDs and sulfasalazine

1 Answer available

What are some strategies for radiographically differentiating between erosions secondary to erosive osteoarthritis versus psoriatic arthritis involving the DIP joints?

1 Answer available

How do you differentiate between axial psoriatic arthritis and axial spondylitis with psoriasis, and is it important to distinguish between these two conditions from a prognostic and treatment perspective?

1 Answer available

Papers discussed in this category

Arthritis Rheumatol, 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Ann. Rheum. Dis., 2019 Sep 28

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Lancet,

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

Arthritis & rheumatology (Hoboken, N.J.), 2016-05

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Arthritis Rheumatol, 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Rheumatology (Oxford),

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Rheumatology (Oxford),

Axial disease in psoriatic arthritis.

Clin. Exp. Rheumatol., 2016 Dec 13

Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis.

Lancet, 2015 Oct 01

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

J Rheumatol Suppl,

GRAPPA 2018 Project Report.

Nat Rev Rheumatol,

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.

Rheumatology (Oxford),

Treatment guidelines in psoriatic arthritis.

Ann Rheum Dis, 2015 Dec 07

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

J Med Imaging Radiat Oncol,

Gull-wing deformity: Osteoarthritis.

J Ultrason, 2016 Mar 29

Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features.

Annals of the rheumatic diseases, 2017-04

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Arthritis Care Res (Hoboken), 2018 Aug

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Arthritis Care Res (Hoboken),

Measuring Outcomes in Psoriatic Arthritis.

Curr Med Chem,

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.

Pathology, 2017 Mar 11

The role of interleukin-17A in the pathogenesis of kidney diseases.

Arthritis Care Res (Hoboken), 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis Rheumatol, 2022 Feb 07

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.

Annals of internal medicine, 2018-01-16

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

J Immunother Cancer,

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.

Related Topics